A new report by the National Audit Office (NAO) has shown the government has made patchy progress in meeting objectives for improving services for people with neurological conditions.
Progress was reviewed against recommendations made by the House of Commons Public Accounts Committee in 2012.  Read on. 

A Scottish GP and former government advisor is facing charges of misconduct over his treatment of a number of patients, including a child.

Dr Tom Gilhooly runs the Essential Health Clinic in Glasgow which offers alternative treatments for people with multiple sclerosis (MS) and other autoimmune conditions. Read on.

Calling all people with MS and health professionals! We need your help to shape our response to a consultation on the key areas for improving services for people with MS.

Following the publication last year of the NICE Guideline for the management of MS in primary and secondary care (Clinical Guideline 186), NICE is now consulting on the key priorities that will help drive service improvement and improve outcomes for people with MS. These are set out in the draft NICE quality standard Multiple sclerosis in adults: diagnosis and management.  Read on. 

Plegridy should be available on the Welsh NHS within three months, so neurologists should be able to prescribe it from late October 2015. Plegridy was approved for NHS treatment in Scotland in January. The regulatory bodies for England (NICE) and Northern Ireland have not yet considered Plegridy.  Read on.

Started in 1988, the Independent Living Fund (ILF) has provided financial support to people with disabilities across the UK.

From Wednesday, 1 July, it will no longer exist in England, while Wales, Scotland and Northern Ireland have made different plans for the fund.

ILF users in England have been protesting since the closure was announced in 2010. Read on

Professor Alastair Compston has been awarded the first ever ‘Richard and Mary Cave Award for Services to People with multiple sclerosis’.

Professor Compston’s commitment and perseverance from the early 1990s led to the development of Lemtrada (alemtuzumab) – one of the most effective first line treatments ever approved for MS. For some people, using the drug has meant they’ve been able to live symptom free for up to ten years.  Read on.

Disabled people should not have their benefits cut – in fact they should receive more support from the state, according to an MS Society survey.

A poll of 1,000 people by One Poll found that 67% agreed disabled people should receive more financial support from the state, to help them live independent lives. Read on.